Immunotherapy: Open Access
Open Access

Ping-sheng Hu

Publications

• Research Article
  T Cell-Mediated Immunotherapy Boosts Clinical Efficacy in the Treatment
  Author(s): Hua Zhang, Yun-hong Huang, Yuan Yang, Qiang-xing Zeng, Xing-nan Zeng, Feng Gou, De-zhuang Hu, Jing-ling Tang, Jin Xiu and Ping-sheng HuHua Zhang, Yun-hong Huang, Yuan Yang, Qiang-xing Zeng, Xing-nan Zeng, Feng Gou, De-zhuang Hu, Jing-ling Tang, Jin Xiu and Ping-sheng Hu
  
  To investigate the anti-tumor efficacy and safety of adoptive cell therapy for the treatment of relapsed, refractory or chemotherapy-resistant lymphoma, we conducted a pilot clinical study using autologous anti-CD3 expanded T cells derived from patients with the diseases. A total of 12 patients, who were pathologically diagnosed with malignant lymphoma at various stages were enrolled in the study. PBMCs from the immunotherapy group were collected and expanded by anti-CD3 in the presence of IFNγ and IL2. The expanded T cells were then infused back to the patients, who were assessed for changes in lymphocyte subgroups, tumor-related biological parameters, imaging characteristics, and the condition of remission and survival. The overall response rate (ORR) to the therapy was 66.7% of the treated patients achieving the complete response (CR) and partial response (PR), with a median .. View More»
  DOI: 10.4172/2471-9552.1000148

  Abstract PDF

Relevant Topics